# Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

Study · id `cardio:ct-nct06317805` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06317805](<https://clinicaltrials.gov/study/NCT06317805>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06317805

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 110 participants.

## Technical summary

Registry record NCT06317805. Randomized; no masking; primary purpose treatment. Start 2023-12-06 (actual); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT06317805, source copy `cardio:ctgov-nct06317805-2026-10-29`, retrieved 2026-10-31)
- Started: 2023-12-06 (actual) (ClinicalTrials.gov record NCT06317805, source copy `cardio:ctgov-nct06317805-2026-10-29`, retrieved 2026-10-31)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT06317805, source copy `cardio:ctgov-nct06317805-2026-10-29`, retrieved 2026-10-31)
- Completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT06317805, source copy `cardio:ctgov-nct06317805-2026-10-29`, retrieved 2026-10-31)
- Countries: Argentina; Austria; Czechia; France; Germany; Hungary; Italy; Poland; Portugal; Romania; Spain; Uruguay (ClinicalTrials.gov record NCT06317805, source copy `cardio:ctgov-nct06317805-2026-10-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06317805-2026-10-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
- Acronym: TripleTRE
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Generic treprostinil sodium + Standard of Care (Double Oral)
- Intervention (Drug): Standard of Care - Double Oral
- Lead sponsor: AOP Orphan Pharmaceuticals AG
- Lead sponsor class: INDUSTRY
- Collaborator: ANOVA CRO s.r.o.
- Collaborator class: UNKNOWN
- Collaborator: PharmaLex Belgium
- Collaborator class: UNKNOWN
- Collaborator: Aixial s.r.o.
- Collaborator class: UNKNOWN
- Collaborator: GCP-Service International Ltd. & Co. KG
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 73d3fb4712de185d62e8cfedefe3946277ed654ae8a09d5cd2b101b48e38cee1
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
